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Abstract Studies investigating the magnitude and breath of
protective immune responses after primary and subsequent
norovirus infections in pediatric populations are limited. We
investigated incidence of norovirus infections and serological
responses in a child from longitudinal stool and serum sam-
ples collected from birth to 2 years of age. Four consecutive
infections with distinct genotypes of norovirus were detected.
Serum antibodies were genotype-specific offering no protec-
tion to reinfection with heterologous virus.
Conclusion: This study describes norovirus-specific sero-
logical responses in a child with four consecutive norovirus
infection during the first 2 years of life. The response is type-
specific and does not protect from a subsequent infection with
a heterologous virus.
What is Known:
• Correlates of protection to norovirus infection and disease are not yet
determined, and most of the presently available data concern adult
population.
What is New:
• This manuscript describes serological immune responses after primary
and subsequent infections in a child during the first 2 years of life.
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Introduction
Noroviruses (NoVs) cause great burden of acute gastroenter-
itis worldwide in children under 5 years of age with approxi-
mately 200,000 deaths annually [1]. The virus is genetically
highly diverse with more than 30 genotypes belonging to six
genogroups (GI–GVI) [2]. NoV infections in children
are associated with GI and GII, with genotype GII.4
being predominant for a long period of time [2].
These infections are acquired early in life, and there is
limited knowledge on protective immune responses and
duration of protection in natural infection in children. A
longitudinal study of NoV infection in young children
has recently demonstrated that reinfections with distinct
genotypes commonly happen [3,4], but the immunity
was not directly measured. In a recent case report [5],
NoV-specific mucosal antibodies did not protect a child
from re-infection with heterologous NoV. In here, we
report a child followed from birth to 2 years of age
with four NoV infections and emergence of acquired
NoV-specific serum IgG and blocking antibodies. NoV-
specific serum antibodies, which block binding of NoV
capsid-derived virus-like particles (VLPs) to the host
cell attachment factors, histo-blood group antigens
(HBGAs), are considered as correlates of protection to
NoV infection [6].
Materials and methods
A healthy newborn was recruited in 2001 into the prospective
Type 1 Diabetes Prediction and Prevention (DIPP) Study
starting at birth [7]. The study was approved by the ethics
committee of the University of Oulu and Oulu University
Hospital and a written informed consent was obtained from
the parents. Serum samples were collected at 0 (cord blood), 3,
6, 12, 18, and 25 months of age, and stool samples were
collected monthly from 4 to 19 months of age (Table 1).
Reverse transcription-PCR (RT-PCR) and ORF1 polymer-
ase (region A) sequencing were used for detecting NoV geno-
type from stool suspensions according to the well-established
methods [8]. NoV GI.3 and GII.4 VLPs cloned from original
patient sequences from 2002 (GI.3, GenBank reference strain
accession no. AF414403) and 1999 (GII.4, AF080551) were
produced in baculovirus-insect cell expression system as ear-
lier described [9]. These VLPs were chosen as antigens to
detect NoV GI- and GII-specific IgG antibody responses
using an ELISA method [10] as these sequences originated
near the time of serum collections in this study (2001–2003,
respectively). Briefly, VLPs were coated in phosphate-
buffered saline (0.5 μg/ml) on 96-well polystyrene plates
(Costar, Corning, NY, USA). Twofold serial dilutions of se-
rum samples, starting at 1:100, were incubated on blocked
plates for 1 h at 37 °C. Bound antibodies of serially diluted
sera were detected with goat anti-human IgG-HRP
(Invitrogen, CA, USA) followed by o-phenylenediamine
dihydrochloride (OPD) substrate (Sigma-Aldrich, MO,
USA). Optical density (OD) was measured, and a mean OD
≥0.100 was considered positive. End-point titer was expressed
as a reciprocal of final serum dilution having positive OD.
Seroconversion was defined as at least fourfold increase in
successive serum end-point titer. Serum antibodies able to
block binding of GI.3 and GII.4 VLPs to HBGAs in human
saliva and therefore potentially neutralize the virus were tested
in blocking assay as previously described [10]. Briefly,
96-well plates were coated with type A saliva from a
secretor-positive adult at 1:3000 dilution. Serially, two-
fold diluted sera (starting dilution 1:50) preincubated
with GI.3 or GII.4 VLPs (0.1 μg/ml) for 1 h at 37 °C
were added to the plates. VLPs without serum were
used as maximum binding controls. Bound VLPs were
detected with NoV genotype-specific mouse sera and
anti-mouse IgG-HRP (Sigma-Aldrich) and OPD sub-
strate. Blocking index (%) was calculated as 100 %
− [(OD wells with VLP serum mix/OD wells without
serum; maximum binding)×100]. Blocking titer 50
(BT50) was determined as the reciprocal of the final
serum dilution that blocked at least 50 % of VLPs
binding to the HBGA.
Results
Four different NoV infections, three with GII (GII.6, GII.4,
and GII.2) and one with GI (GI.3) NoVs, were detected byRT-
PCR during a period of 15 months (Table 1). The child ac-
quired febrile primary infection with GII.6 already at 4 months
indicating that maternal antibodies although present in cord
blood (end-point titer 800 to GI.3 and 3200 to GII.4, respec-
tively) did not protect the child from NoV infection (Table 1
and Fig. 1). However, the cord blood antibodies completely
lacked blocking potential of both VLPs (Fig. 1). Following the
first infection, IgG seroconversion to GI.3 and GII.4 was de-
tected at 6 months (Table 1 and Fig. 1). Although the levels of
antibodies pertained until 12 months of age, they did not con-
fer protection from a subsequent infection with GI.3 NoV at
13 months of age, and even though GII.4-specific antibodies
detected at 12 month at a serum dilution 1:50 blocked 98 % of
GII.4 VLPs binding to the HBGA receptor/s (Fig. 1), they did
not protect the child from acquiring GII.4 infection at
15 months of age (Table 1). Clinically, the child experienced
a prolonged diarrhea for a period of 3–4 weeks at the age of
13–14 months. During that period, the child might have ex-
perienced the two sequential infections with GI.3 and GII.4
NoVs. After the infections with GI.3 and GII.4, serum anti-
body levels to both VLPs measured at 18 months increased 16
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times (end-point titers 51,200 and 102,400, respectively) com-
pared to the pre-infection titers at 12 months (end-point titers
3200 and 6400) (Fig. 1). The high antibody level to GII.4
genotype (end-point titer 102,400 with 97 % blocking) did
not prevent further infection with heterologous GII.2 NoV
genotype already in the following month at the age of
19 months (Table 1 and Fig. 1), when the child again had
typical clinical symptoms of gastroenteritis. These results
Fig. 1 Norovirus-specific serum
IgG antibodies in a child from 0 to
25 months of age. Serum samples
collected at 0, 3, 6, 12, 18, and
25 months were tested for GI.3-
and GII.4-specific antibodies in
ELISA and blocking assays. End-
point titer is expressed as a recip-
rocal of final serum dilution giv-
ing an OD≥0.100. Blocking in-
dex (%) is shown for serum dilu-
tions 1:50. Blocking titer 50
(BT50), reciprocal of the final se-
rum dilution with 50 % blocking
activity. Approximate time points
of norovirus infections are indi-
cated by arrows. GE stands for
gastroenteritis symptoms reported
Table 1 Detection of norovirus
in stool samples and GI.3- and
GII.4-specific antibodies in serum
samples of a child from 0 to











0 (cord blood) No Yes + +
3 No Yes + +
4 Yes No GII.6
5 Yes No −
6 Yes Yes − ++ ++
7 Yes No −
8 Yes No −
10 Yes No −
11 Yes No −
12 No Yes + +
13 Yes No GI.3
14 Yes No −
15 Yes No GII.4
16 Yes No −
17 Yes No −
18 No Yes ++ ++
19 Yes No GII.2
25 No Yes + +
− negative, + positive, ++ indicates fourfold increase in GI.3- and GII.4-specific end-point titer
Eur J Pediatr (2015) 174:1679–1683 1681
show complete lack of cross-protection between the GII
NoVs. In 7 months’ time (from 18–25 months), the child
had retained only a half of GI.3 (end-point titer 25,600) and
1/8 of GII.4-specific antibodies (end-point titer 12,800) in the
serum (Fig. 1).
Discussion
Our study shows that a child can acquire as many as four
consecutive NoV infections before the age of 2 years.
Upon primary infection with GII.6 at 4 months, the child
presented fever, but as there were no signs of vomiting
or diarrhea, the infection was probably mild or asymp-
tomatic, as recently reported [3]. Maternal antibodies
present prior to the infection might have protected from
severe disease but not the infection. A seroconversion to
GII.4 was detected after the primary infection already at
6 months, but increase in blocking antibodies to GII.4
was detected at 12 months, suggesting that heterologous
blocking antibodies may take longer time to develop.
Although the child generated remarkable homologous se-
rum antibody titer (GII.4-specific end-point titer 102,400,
respectively) with high blocking activity (BT50 200), the
immunity was not cross-protective and the child
remained prone to infections with new GII.2 NoV geno-
type. The results presented here are in contrast to the
findings observed in rotavirus infections, where protec-
tive antibody titers were achieved after two consecutive
symptomatic or asymptomatic rotavirus infections in
children less than 2 years of age [11]. The results in
the present study suggest that NoV protective immunity
in young children is type-specific. However, further stud-
ies in large pediatric populations are needed to address
the magnitude, specificity, and duration of immune re-
sponses required for protection to NoV infection in
young children. As children up to 2 years of age are
highly vulnerable to infection and severe medically
attended gastroenteritis, NoV vaccination of this target
population is needed [12].
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